Payment overview · 2025
General Payments
$1,702.59
48 reported records · 15 companies
Healthcare provider profile · identity verified
Tsung Peter Wong, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LIVERMORE, CA · NPI 1073513156
Verified facts
What the public records show
CMS Open Payments records show Tsung Peter Wong, MD received $1,702.59 in general payments during 2025 across 48 reported records.
GlaxoSmithKline, LLC. accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $351.65 | 20.6% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $331.49 | 19.5% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $233.46 | 13.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $175.92 | 10.3% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $158.48 | 9.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $121.83 | 7.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.61 | 4.8% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $58.26 | 3.4% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.91 | 2.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.12 | 2.5% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.58 | 1.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.22 | 1.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.79 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.45 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.82 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,702.59 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $228.38 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $212.63 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $191.30 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $180.09 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $158.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $115.88 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $108.79 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $92.78 | 11 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.13 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $63.54 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.12 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.49 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $7.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 147 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
147 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
98 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 512 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 383 | 108 |
| Losartan Potassium | Losartan Potassium | 289 | 96 |
| Lisinopril | Lisinopril | 268 | 72 |
| Gabapentin | Gabapentin | 265 | 74 |
| Metformin Hcl | Metformin Hcl | 216 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 158 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 147 | 29 |
| Tramadol Hcl | Tramadol Hcl | 143 | 41 |
| Furosemide | Furosemide | 142 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 50 |
| Eliquis | Apixaban | 128 | 29 |
| Sertraline Hcl | Sertraline Hcl | 117 | 19 |
| Donepezil Hcl | Donepezil Hcl | 116 | 19 |
| Finasteride | Finasteride | 108 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 31 |
| Trazodone Hcl | Trazodone Hcl | 100 | 25 |
| Rybelsus | Semaglutide | 98 | 19 |
| Famotidine | Famotidine | 97 | 35 |
| Omeprazole | Omeprazole | 97 | 29 |
| Mirtazapine | Mirtazapine | 94 | 25 |
| Potassium Chloride | Potassium Chloride | 94 | 27 |
| Memantine Hcl | Memantine Hcl | 93 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 84 | 40 |
| Alendronate Sodium | Alendronate Sodium | 77 | 23 |
| Atenolol | Atenolol | 73 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | 15 |
| Ezetimibe | Ezetimibe | 64 | 19 |
| Prednisone | Prednisone | 64 | 17 |
| Allopurinol | Allopurinol | 62 | 17 |
| Benazepril Hcl | Benazepril Hcl | 60 | 14 |
| Simvastatin | Simvastatin | 55 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 14 |
| Lorazepam | Lorazepam | 51 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 17 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Vascepa | Icosapent Ethyl | 49 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 11 |
| Carvedilol | Carvedilol | 44 | 17 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | 14 |
| Alprazolam | Alprazolam | 41 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 37 |
| Valsartan | Valsartan | 38 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Cephalexin | Cephalexin | 34 | 18 |
| Lovastatin | Lovastatin | 34 | 11 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Nystatin | Nystatin | 32 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | 12 |
| Metformin Hcl Er | Metformin Hcl | 28 | 11 |
| Temazepam | Temazepam | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | 11 |
| Silodosin | Silodosin | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 13 |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 11 |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Cefaclor | Cefaclor | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Matzim La | Diltiazem Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,702.59 · 48 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, FASENRA, FREESTYLE LIBRE 3, JARDIANCE, KEVEYIS, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NUZYRA, Ozempic, PREVNAR 20, REXULTI, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error